NEPH
Nephros, Inc.
NEPH has a slight edge over OSCR overall, supported by stronger modeled upside and stronger valuation.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
NEPH Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Under pressure | |
| Strong |
NEPH's revenue, profitability and balance sheet are currently healthy, but its cash flow is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
NEPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $3.31 | — |
| Current | 18x | $3.31 | — |
| Cheap | 27x | $4.78 | +44% |
| Fair | 34x | $6.13 | +85% |
| Expensive | 50x | $8.99 | +172% |
Historical ranges are pointers, not guarantees.
NEPH's PE is in its cheap range at 18x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over NEPH in the historical PE scenario, which offers more potential upside but is not a forecast.
NEPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for NEPH, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
NEPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.23 | +30% |
| Q3 2026 | $0.18 | +29% |
| Q2 2026 | $0.16 | +23% |
| Q1 2026 | $0.07 | -12% |
| Q4 2025 | $0.11 | +1000% |
| Q3 2025 | $0.14 | +$0.23 |
| Q2 2025 | $0.13 | +$0.26 |
| Q1 2025 | $0.08 | +$0.22 |
| Q4 2024 | $0.01 | +$0.16 |
NEPH has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
NEPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.6M | +18% |
| Q2 2026 | $6M | +36% |
| Q1 2026 | $5.2M | +6.9% |
| Q4 2025 | $4.7M | +22% |
| Q3 2025 | $4.8M | +35% |
| Q2 2025 | $4.4M | +36% |
| Q1 2025 | $4.9M | +38% |
| Q4 2024 | $3.9M | +19% |
NEPH's revenue has grown year over year for eight quarters in a row: $6M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.9% | +2.3 points |
| Q2 2026 | 20% | +15 points |
| Q1 2026 | 1.9% | -9.8 points |
| Q4 2025 | 0.4% | -7.8 points |
| Q3 2025 | 6.6% | +0.7 points |
| Q2 2025 | 5.6% | +15 points |
| Q1 2025 | 12% | +17 points |
| Q4 2024 | 8.2% | +28 points |
NEPH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over NEPH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
NEPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.7M | -619% |
| Q4 2025 | $230K | -82% |
| Q1 2025 | $322K | +$994K |
| Q4 2022 | -$195K | +$140K |
| Q3 2022 | -$170K | +$753K |
| Q2 2022 | -$1.2M | -$1.1M |
| Q1 2022 | -$1.8M | -$1.8M |
| Q4 2021 | -$335K | +$1.2M |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with NEPH at up 58%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
NEPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +91.3K shares |
| 1 year | +1.5% | +163K shares |
| 3 years | +7.1% | +743K shares |
| 5 years | +12% | +1.2M shares |
| Available history | +49% | +3.7M shares |
NEPH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
NEPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.3x | Net Cash |
| Q2 2026 | -2.7x | Net Cash |
| Q1 2026 | -5.0x | Net Cash |
| Q4 2025 | -4.2x | Net Cash |
| Q3 2025 | -3.3x | Net Cash |
| Q2 2025 | -3.4x | Net Cash |
| Q1 2025 | -4.5x | Net Cash |
| Q4 2024 | -26.7x | Net Cash |
NEPH has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over NEPH on leverage, with a lower net debt burden relative to earnings.
NEPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 13.1 | Oversold |
NEPH's weekly RSI is 45 (neutral) and its Stochastic is 13 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
NEPH PE vs Healthcare Sector
| Metric | NEPH | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 1 | 29 | 28 pts below |
NEPH is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over NEPH on valuation relative to its sector.
NEPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.48 | 4.9% below |
| 20 week MA | $3.80 | 13% below |
| 50 week MA | $3.82 | 13% below |
| 100 week MA | $3.46 | 4.3% below |
| 200 week MA | $2.69 | 23% above |
NEPH has fallen below most of its moving averages, though it's still 23% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over NEPH on trend strength, trading above more of its moving averages.
NEPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.1 | $8.08 | -20% |
| 2021 | $8.08 | $6.00 | -26% |
| 2022 | $6.00 | $1.05 | -83% |
| 2023 | $1.05 | $3.46 | +230% |
| 2024 | $3.46 | $1.49 | -57% |
| 2025 | $1.49 | $4.93 | +231% |
| 2026 YTD | $4.93 | $3.31 | -33% |
NEPH's yearly returns have swung widely, from +231% in 2025 to −83% in 2022. It's down 33% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over NEPH on returns for 2026, with the stronger performance.